Restorbio
Innovative medicines targeting aging biology to prevent or treat age-related diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
$40.0m | Series B | ||
| Total Funding | 000k | ||
| EUR | 2019 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
resTORbio is a biopharmaceutical company focused on developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. The company operates in the healthcare and pharmaceutical market, primarily serving older adults who are at risk of or suffering from chronic diseases associated with aging. resTORbio's business model revolves around the discovery, development, and commercialization of drugs that modulate specific biochemical pathways, such as the TORC1 pathway, which are believed to regulate aging and its related diseases. The company generates revenue through the development and sale of these therapeutic drugs, as well as through partnerships and collaborations with other pharmaceutical companies.
Keywords: biopharmaceutical, aging, innovative medicines, TORC1 pathway, chronic diseases, older adults, healthcare, pharmaceutical, drug development, commercialization.